In addition to manufacturing standard lentiviruses, VIVEbiotech develops proprietary vectors with its patented technology called LENTISOMA.

As Dr Linazasoro indicated, VIVEbiotech works in the medicine of the future, which will offer the 5 P-s: preventive, participative, precise, personalized and predictive.

The interview was published yesterday, March 18, and can be read here.